BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time. A live audio webcast of the ...

Company Overview - Day One Biopharmaceuticals, Inc. is focused on developing and commercializing targeted therapies for life-threatening diseases, particularly in pediatric cancer [3][4] - The company aims to address the critical unmet need in pediatric cancer therapeutic development, inspired by the initial conversations between physicians and families regarding cancer diagnosis and treatment [3] Upcoming Events - Management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 4:00 p.m. EST [1] - A live webcast of the discussion will be available on the company's Media & Investors page, with an archived replay accessible for 30 days post-event [2] Pipeline and Partnerships - Day One's pipeline includes targeted cancer treatments such as tovorafenib (OJEMDA™) and DAY301 [4] - The company collaborates with leading clinical oncologists, families, and scientists to identify and develop important cancer treatments [4] Communication Channels - Day One utilizes its Investor Relations website, X handle, and LinkedIn page to disseminate news, announcements, and financial performance updates [5]

Company Overview - Day One Biopharmaceuticals is focused on developing and commercializing targeted therapies for life-threatening diseases, particularly in pediatric cancer [3][4] - The company aims to address the critical unmet need in pediatric cancer therapeutic development, inspired by the initial conversations between physicians and families regarding cancer diagnosis and treatment [3] Upcoming Events - Day One will host a live conference call and webcast on May 6, 2025, at 4:30 p.m. ET to report financial results and discuss corporate progress for Q1 2025 [1] - The live audio of the webcast will be accessible on the Day One Investors & Media page, with an archived version available for replay for 30 days following the event [2] Pipeline and Collaborations - The company's pipeline includes tovorafenib (OJEMDA™), DAY301, and a VRK1 inhibitor program [4] - Day One collaborates with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments [4] Communication Channels - Day One utilizes its Investor Relations website, X handle, and LinkedIn page to disseminate news, announcements, and financial performance updates [5]